Bruce D. Jackson
Stock Analyst at Benchmark
(3.89)
# 618
Out of 5,245 analysts
14
Total ratings
73.33%
Success rate
7.29%
Average return
Main Sectors:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFRI Biofrontera | Downgrades: Speculative Buy | $3 | $0.8073 | +271.61% | 1 | May 19, 2026 | |
| ABT Abbott Laboratories | Maintains: Buy | $145 → $120 | $87.41 | +37.28% | 1 | Apr 17, 2026 | |
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $21 → $15 | $8.08 | +85.64% | 2 | Apr 6, 2026 | |
| HUMA Humacyte | Downgrades: Speculative Buy | $10 → $1 | $1.05 | -4.76% | 3 | Mar 31, 2026 | |
| GNLX Genelux | Maintains: Speculative Buy | $23 → $20 | $2.92 | +584.93% | 1 | Mar 20, 2026 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $0.6 → $6 | $5.59 | +7.33% | 3 | Mar 16, 2026 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.383 | +161.10% | 1 | Nov 20, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $137.30 | -3.86% | 1 | Oct 31, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $6.70 | +362.69% | 1 | Sep 10, 2025 |
Biofrontera
May 19, 2026
Downgrades: Speculative Buy
Price Target: $3
Current: $0.8073
Upside: +271.61%
Abbott Laboratories
Apr 17, 2026
Maintains: Buy
Price Target: $145 → $120
Current: $87.41
Upside: +37.28%
Unicycive Therapeutics
Apr 6, 2026
Maintains: Speculative Buy
Price Target: $21 → $15
Current: $8.08
Upside: +85.64%
Humacyte
Mar 31, 2026
Downgrades: Speculative Buy
Price Target: $10 → $1
Current: $1.05
Upside: -4.76%
Genelux
Mar 20, 2026
Maintains: Speculative Buy
Price Target: $23 → $20
Current: $2.92
Upside: +584.93%
Harvard Bioscience
Mar 16, 2026
Maintains: Speculative Buy
Price Target: $0.6 → $6
Current: $5.59
Upside: +7.33%
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.383
Upside: +161.10%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $137.30
Upside: -3.86%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $6.70
Upside: +362.69%